All In Biotech

Drug Trial Radar · NCT06503679

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Midazolam, Repaglinide, Digoxin, and Rosuvastatin in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Jul 16, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.

Conditions

  • Healthy

Interventions

  • LY4100511 (DC-853) Dose 1Drug

    Administered orally

  • LY4100511 (DC-853) Dose 2Drug

    Administered orally

  • LY4100511 (DC-853) Dose 3Drug

    Administered orally

  • MidazolamDrug

    Administered orally

  • RepaglinideDrug

    Administered orally

  • DigoxinDrug

    Administered orally

  • RosuvastatinDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Midazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  2. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  3. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Repaglinide, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  4. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Digoxin, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  5. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Midazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  6. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  7. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Repaglinide,in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  8. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Digoxin, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  9. PK: Maximum Observed Concentration (Cmax) of Midazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  10. PK: Maximum Observed Concentration (Cmax) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  11. PK: Maximum Observed Concentration (Cmax) of Repaglinide, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose
  12. PK: Maximum Observed Concentration (Cmax) of Digoxin, in the absence or presence of steady-state LY4100511Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.